{"id":110650,"date":"2026-05-06T16:00:51","date_gmt":"2026-05-06T14:00:51","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-screening-platform-manager-de-nuage-therapeutics-tenemos-una-tecnologia-aplicable-a-un-tipo-de-proteina-que-nos-permite-obtener-directamente-la-funcionalidad-de-nuestras-molecul\/"},"modified":"2026-05-11T10:26:40","modified_gmt":"2026-05-11T08:26:40","slug":"mireia-pesarrodona-screening-platform-manager-de-nuage-therapeutics-tenemos-una-tecnologia-aplicable-a-un-tipo-de-proteina-que-nos-permite-obtener-directamente-la-funcionalidad-de-nuestras-molecul","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/mireia-pesarrodona-screening-platform-manager-de-nuage-therapeutics-tenemos-una-tecnologia-aplicable-a-un-tipo-de-proteina-que-nos-permite-obtener-directamente-la-funcionalidad-de-nuestras-molecul\/","title":{"rendered":"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: \u00abTenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas\u00bb"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/nuage-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Nuage Therapeutics<\/a> es una spin-off biotecnol\u00f3gica que ha desarrollado una tecnolog\u00eda innovadora que permite estudiar las prote\u00ednas intr\u00ednsecamente desordenadas (IDPs) para el desarrollo de una nueva generaci\u00f3n de terapias transformadoras. Esta estrategia abre una nueva v\u00eda para dise\u00f1ar terapias contra prote\u00ednas que hasta ahora se consideraban inalcanzables con f\u00e1rmacos.<\/strong><\/p>\n<p>\u00abLo que nos diferencia es que tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas\u00bb, explica en esta entrevista <strong>Mireia Pesarrodona<\/strong>, Screening Platform Manager de Nuage Therapeutics. La plataforma patentada de la empresa permite profundizar en las estructuras de las IDPs adoptadas temporalmente. Esto permite a los investigadores dise\u00f1ar f\u00e1rmacos capaces de reconocerlas y actuar sobre ellas, algo que antes era imposible. Este descubrimiento representa un cambio de paradigma en el descubrimiento de f\u00e1rmacos, convirtiendo el \u201cdesorden\u201d proteico en una oportunidad terap\u00e9utica.<\/p>\n<p>La empresa, fundada por investigadores del IRB Barcelona e ICREA, combina investigaci\u00f3n b\u00e1sica de vanguardia con una clara vocaci\u00f3n translacional. Desde sus inicios, Nuage Therapeutics ha apostado por construir una plataforma tecnol\u00f3gica robusta capaz de identificar y caracterizar interacciones en prote\u00ednas intr\u00ednsecamente desordenadas con una precisi\u00f3n sin precedentes. \u00abAl principio buscamos apoyo externo para implementar tecnolog\u00edas, pensando que nos aportar\u00edan todo el conocimiento y la experiencia. Pero despu\u00e9s hemos visto que, en realidad, nosotros hemos aportado mucho conocimiento sobre este tipo de prote\u00ednas en concreto\u00bb, afirma la investigadora.<\/p>\n<p><iframe loading=\"lazy\" title=\"Coffee Connection: Entrevista a Mireia Pesarrodona, Screening Platform Manager a Nuage Therapeutics\" src=\"https:\/\/www.youtube.com\/embed\/e9u3FULwE98\" width=\"1401\" height=\"788\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nuage Therapeutics es una spin-off biotecnol\u00f3gica que ha desarrollado una tecnolog\u00eda innovadora que permite estudiar las prote\u00ednas intr\u00ednsecamente desordenadas (IDPs) para el desarrollo de una nueva generaci\u00f3n de terapias transformadoras&#8230;.<\/p>\n","protected":false},"author":14,"featured_media":110647,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[37],"tags":[293],"class_list":["post-110650","post","type-post","status-publish","format-standard","has-post-thumbnail","category-pcb","tag-nuage-therapeutics-es"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: &quot;Tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas&quot; - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"Entrevistamos a Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: &quot;Tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas&quot; - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Entrevistamos a Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T14:00:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-11T08:26:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: \u00abTenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas\u00bb\",\"datePublished\":\"2026-05-06T14:00:51+00:00\",\"dateModified\":\"2026-05-11T08:26:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/\"},\"wordCount\":286,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/mini_nuage_noti-1.jpg\",\"keywords\":[\"Nuage Therapeutics\"],\"articleSection\":[\"PCB\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/\",\"name\":\"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: \\\"Tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas\\\" - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/mini_nuage_noti-1.jpg\",\"datePublished\":\"2026-05-06T14:00:51+00:00\",\"dateModified\":\"2026-05-11T08:26:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"Entrevistamos a Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/mini_nuage_noti-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/mini_nuage_noti-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: &#8220;Tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: \"Tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas\" - Parc Cient\u00edfic de Barcelona","description":"Entrevistamos a Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/","og_locale":"es_ES","og_type":"article","og_title":"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: \"Tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas\" - Parc Cient\u00edfic de Barcelona","og_description":"Entrevistamos a Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics","og_url":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-05-06T14:00:51+00:00","article_modified_time":"2026-05-11T08:26:40+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Paula Ca\u00f1al","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: \u00abTenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas\u00bb","datePublished":"2026-05-06T14:00:51+00:00","dateModified":"2026-05-11T08:26:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/"},"wordCount":286,"image":{"@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","keywords":["Nuage Therapeutics"],"articleSection":["PCB"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/","url":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/","name":"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: \"Tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas\" - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","datePublished":"2026-05-06T14:00:51+00:00","dateModified":"2026-05-11T08:26:40+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"Entrevistamos a Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-sreening-platform-manager-de-nuage-therapeutics-el-que-ens-diferencia-es-que-tenim-una-tecnologia-aplicable-a-un-tipus-de-proteina-que-ens-permet-obtenir-directament-la-funciona\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Mireia Pesarrodona, Screening Platform Manager de Nuage Therapeutics: &#8220;Tenemos una tecnolog\u00eda aplicable a un tipo de prote\u00edna que nos permite obtener directamente la funcionalidad de nuestras mol\u00e9culas&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/110650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=110650"}],"version-history":[{"count":2,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/110650\/revisions"}],"predecessor-version":[{"id":110653,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/110650\/revisions\/110653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/110647"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=110650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=110650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=110650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}